Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
'Kiara Advani's Pregnancy Was Eye-Opening': Sidharth Malhotra Praises Wife, Says Life Changed After 4-Month-Old Daughter's Birth
Pimpri-Chinchwad: PCMC Faces Heat As Dog Bite Cases Spike; Just 844 Sterilisations Conducted This Year
When Adnan Sami Dropped Weight From 230 Kgs To 75 Kgs Without Fad Diets: Here's What He Followed
Mumbai: 6-Year-Old Boy Beaten With Wire And Dog Leash In Andheri; Father Arrested After FIR
